Brief report: The uricase mutation in humans increases our risk for cancer growth
Level 5 - mechanism / opinion, no new human data
Preclinical animal model study (in vivo mouse experiment)
OpenAlex W3200024613 · doi:10.1186/s40170-021-00268-3
What was done
Experiments were conducted in mice with uricase inactivated via genetic knockout or pharmacological inhibition with oxonic acid, alongside transgenic mice expressing uricase. Mice were injected with breast cancer cells and followed for 4 weeks to evaluate tumor progression.
What was found
Inhibition or knockout of uricase was associated with increased tumor growth and metastases in mice, while transgenic uricase mice showed reduced tumor growth. The abstract reports no numerical values, effect sizes, or statistical metrics.
Why it matters
This study suggests a mechanistic link between the evolutionary silencing of uricase and heightened susceptibility to uric-acid- and fructose-driven cancer progression.
Limits
Findings are limited to animal models using one breast cancer cell line and cannot establish causality or risk magnitude in humans. The abstract omits sample sizes, specific measurements, variance, and p-values.
Cited by
- supports A mutation in uricase occurred in ancestral great apes and humans approximately 15 million years ago that eliminated uricase activity.